| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 24 | 2025 | 1240 | 4.100 |
Why?
|
| Cardiovascular Diseases | 17 | 2025 | 788 | 3.170 |
Why?
|
| Myocarditis | 14 | 2024 | 60 | 2.590 |
Why?
|
| Cardiotoxicity | 9 | 2025 | 15 | 2.080 |
Why?
|
| Immunotherapy | 4 | 2025 | 230 | 1.910 |
Why?
|
| Heart Failure | 9 | 2024 | 853 | 1.860 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2025 | 635 | 1.840 |
Why?
|
| Cardiomyopathies | 5 | 2024 | 119 | 1.780 |
Why?
|
| Atrial Fibrillation | 6 | 2024 | 805 | 1.560 |
Why?
|
| Antineoplastic Agents | 6 | 2023 | 631 | 1.510 |
Why?
|
| Percutaneous Coronary Intervention | 5 | 2024 | 160 | 1.460 |
Why?
|
| Coronary Artery Disease | 3 | 2024 | 273 | 1.360 |
Why?
|
| Stroke Volume | 8 | 2024 | 314 | 1.360 |
Why?
|
| Intracranial Hemorrhages | 2 | 2021 | 61 | 1.240 |
Why?
|
| Humans | 80 | 2025 | 59282 | 1.180 |
Why?
|
| Climate Change | 3 | 2025 | 18 | 1.100 |
Why?
|
| Ritonavir | 3 | 2023 | 14 | 1.100 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2024 | 86 | 1.060 |
Why?
|
| Cardiology | 5 | 2024 | 163 | 1.020 |
Why?
|
| Medical Oncology | 7 | 2024 | 57 | 1.010 |
Why?
|
| Water Pollutants, Chemical | 1 | 2025 | 35 | 0.950 |
Why?
|
| Catheter Ablation | 2 | 2024 | 145 | 0.950 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 19 | 0.930 |
Why?
|
| Perioperative Care | 1 | 2025 | 76 | 0.900 |
Why?
|
| Environmental Exposure | 2 | 2025 | 208 | 0.890 |
Why?
|
| Heart Diseases | 3 | 2022 | 206 | 0.880 |
Why?
|
| Stroke | 2 | 2024 | 1127 | 0.870 |
Why?
|
| Nervous System Diseases | 1 | 2025 | 104 | 0.860 |
Why?
|
| Cardiovascular Agents | 2 | 2022 | 98 | 0.790 |
Why?
|
| Overweight | 1 | 2024 | 238 | 0.780 |
Why?
|
| Aged | 27 | 2025 | 13412 | 0.740 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 206 | 0.740 |
Why?
|
| Septal Occluder Device | 1 | 2021 | 11 | 0.740 |
Why?
|
| Risk Factors | 17 | 2025 | 4982 | 0.730 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2023 | 249 | 0.730 |
Why?
|
| Cross Infection | 2 | 2020 | 148 | 0.710 |
Why?
|
| Atrial Appendage | 1 | 2021 | 29 | 0.700 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 50 | 0.690 |
Why?
|
| Drug-Eluting Stents | 2 | 2017 | 51 | 0.690 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 38 | 0.690 |
Why?
|
| Cardiovascular System | 1 | 2020 | 38 | 0.680 |
Why?
|
| Venous Thrombosis | 2 | 2018 | 110 | 0.680 |
Why?
|
| Hypertension | 2 | 2025 | 567 | 0.650 |
Why?
|
| Retrospective Studies | 17 | 2025 | 6071 | 0.640 |
Why?
|
| Middle Aged | 23 | 2025 | 16310 | 0.630 |
Why?
|
| Heart Function Tests | 1 | 2018 | 14 | 0.620 |
Why?
|
| Female | 32 | 2025 | 30695 | 0.620 |
Why?
|
| Medical Overuse | 1 | 2018 | 9 | 0.620 |
Why?
|
| Air Microbiology | 1 | 2018 | 8 | 0.620 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2018 | 7 | 0.620 |
Why?
|
| Heating | 1 | 2018 | 8 | 0.620 |
Why?
|
| Equipment Contamination | 1 | 2018 | 31 | 0.610 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 169 | 0.610 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2018 | 14 | 0.610 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 407 | 0.610 |
Why?
|
| Betacoronavirus | 1 | 2020 | 166 | 0.600 |
Why?
|
| Sarcoidosis | 1 | 2018 | 30 | 0.600 |
Why?
|
| Iliac Vein | 1 | 2018 | 9 | 0.590 |
Why?
|
| Pyrazoles | 1 | 2018 | 64 | 0.590 |
Why?
|
| Registries | 7 | 2024 | 801 | 0.580 |
Why?
|
| Pyrimidines | 1 | 2018 | 130 | 0.580 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 191 | 0.550 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2017 | 13 | 0.550 |
Why?
|
| Vascular Access Devices | 1 | 2017 | 15 | 0.550 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 204 | 0.550 |
Why?
|
| Stents | 2 | 2017 | 461 | 0.540 |
Why?
|
| Obesity | 1 | 2024 | 1166 | 0.530 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2018 | 153 | 0.520 |
Why?
|
| Male | 29 | 2025 | 27727 | 0.520 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 125 | 0.510 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 163 | 0.510 |
Why?
|
| Pharmacovigilance | 3 | 2024 | 13 | 0.500 |
Why?
|
| Thrombolytic Therapy | 1 | 2017 | 184 | 0.500 |
Why?
|
| Treatment Outcome | 10 | 2024 | 5283 | 0.490 |
Why?
|
| Quality of Life | 1 | 2022 | 1137 | 0.480 |
Why?
|
| Adult | 16 | 2025 | 15663 | 0.470 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 3 | 2024 | 45 | 0.470 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 170 | 0.470 |
Why?
|
| Ventricular Function, Left | 5 | 2024 | 257 | 0.470 |
Why?
|
| Risk Assessment | 8 | 2025 | 1920 | 0.460 |
Why?
|
| Aged, 80 and over | 12 | 2025 | 5128 | 0.450 |
Why?
|
| United States | 14 | 2025 | 7385 | 0.440 |
Why?
|
| Endovascular Procedures | 2 | 2017 | 608 | 0.440 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2025 | 113 | 0.430 |
Why?
|
| Cardiologists | 2 | 2023 | 26 | 0.420 |
Why?
|
| Air Pollution | 2 | 2023 | 29 | 0.420 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 349 | 0.420 |
Why?
|
| Electrocardiography | 4 | 2021 | 523 | 0.410 |
Why?
|
| United States Food and Drug Administration | 2 | 2024 | 85 | 0.400 |
Why?
|
| Pandemics | 5 | 2023 | 614 | 0.370 |
Why?
|
| Angioedema | 2 | 2021 | 10 | 0.360 |
Why?
|
| Myocardial Infarction | 3 | 2023 | 862 | 0.340 |
Why?
|
| Acute Coronary Syndrome | 2 | 2023 | 250 | 0.330 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 1118 | 0.320 |
Why?
|
| Anthracyclines | 3 | 2023 | 10 | 0.310 |
Why?
|
| Heart Rate | 2 | 2021 | 307 | 0.300 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 42 | 0.290 |
Why?
|
| Hospitalization | 6 | 2024 | 1290 | 0.290 |
Why?
|
| Cardiac Catheterization | 2 | 2021 | 252 | 0.280 |
Why?
|
| Databases, Factual | 3 | 2025 | 813 | 0.270 |
Why?
|
| Young Adult | 6 | 2024 | 4266 | 0.270 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 55 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 677 | 0.250 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 192 | 0.250 |
Why?
|
| Echocardiography | 2 | 2020 | 457 | 0.250 |
Why?
|
| Incidence | 4 | 2024 | 1236 | 0.240 |
Why?
|
| Mobility Limitation | 1 | 2025 | 47 | 0.240 |
Why?
|
| Predictive Value of Tests | 4 | 2022 | 1025 | 0.240 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2024 | 140 | 0.230 |
Why?
|
| Prevalence | 2 | 2025 | 1252 | 0.230 |
Why?
|
| Adolescent | 6 | 2024 | 5822 | 0.230 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2024 | 3 | 0.230 |
Why?
|
| Bayes Theorem | 1 | 2024 | 109 | 0.230 |
Why?
|
| Metabolic Syndrome | 1 | 2025 | 131 | 0.220 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2373 | 0.220 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2023 | 6 | 0.220 |
Why?
|
| Nutrition Surveys | 1 | 2024 | 129 | 0.220 |
Why?
|
| Amyloidosis | 1 | 2024 | 62 | 0.210 |
Why?
|
| Propensity Score | 1 | 2024 | 144 | 0.210 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2023 | 32 | 0.210 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2023 | 16 | 0.210 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2023 | 96 | 0.200 |
Why?
|
| Drug Interactions | 1 | 2022 | 115 | 0.200 |
Why?
|
| Heart Valve Diseases | 1 | 2023 | 88 | 0.200 |
Why?
|
| Air Pollutants | 1 | 2023 | 76 | 0.200 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2024 | 96 | 0.200 |
Why?
|
| Vinca Alkaloids | 1 | 2021 | 1 | 0.190 |
Why?
|
| Taxoids | 1 | 2021 | 24 | 0.190 |
Why?
|
| Heart | 3 | 2021 | 274 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 299 | 0.190 |
Why?
|
| Aortic Valve Stenosis | 1 | 2024 | 170 | 0.190 |
Why?
|
| Hyperkalemia | 1 | 2021 | 19 | 0.180 |
Why?
|
| Angiotensin II | 1 | 2021 | 23 | 0.180 |
Why?
|
| Shock | 1 | 2021 | 31 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 39 | 0.180 |
Why?
|
| Giant Cells | 1 | 2021 | 15 | 0.180 |
Why?
|
| Medicare | 2 | 2023 | 598 | 0.180 |
Why?
|
| Hypotension | 1 | 2021 | 48 | 0.180 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 283 | 0.180 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 64 | 0.180 |
Why?
|
| Heart Conduction System | 1 | 2021 | 50 | 0.180 |
Why?
|
| Bundle-Branch Block | 1 | 2020 | 14 | 0.180 |
Why?
|
| Biopsy | 2 | 2021 | 411 | 0.180 |
Why?
|
| Action Potentials | 1 | 2021 | 101 | 0.180 |
Why?
|
| Rural Population | 1 | 2022 | 185 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 119 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2022 | 203 | 0.170 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2023 | 211 | 0.170 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 66 | 0.170 |
Why?
|
| Heart Arrest | 1 | 2022 | 161 | 0.170 |
Why?
|
| Kidney Diseases | 1 | 2021 | 169 | 0.170 |
Why?
|
| Atherosclerosis | 1 | 2021 | 146 | 0.160 |
Why?
|
| Asthma | 1 | 2023 | 452 | 0.160 |
Why?
|
| Dementia | 1 | 2022 | 248 | 0.160 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 132 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 168 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 933 | 0.150 |
Why?
|
| Physical Examination | 1 | 2018 | 103 | 0.150 |
Why?
|
| Adenine | 1 | 2018 | 47 | 0.150 |
Why?
|
| Piperidines | 1 | 2018 | 54 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 1 | 2018 | 59 | 0.150 |
Why?
|
| Global Health | 1 | 2019 | 167 | 0.150 |
Why?
|
| Operating Rooms | 1 | 2018 | 55 | 0.150 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 89 | 0.150 |
Why?
|
| Comorbidity | 2 | 2019 | 1078 | 0.140 |
Why?
|
| Time Factors | 3 | 2024 | 3614 | 0.140 |
Why?
|
| Anticoagulants | 2 | 2022 | 477 | 0.140 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2024 | 753 | 0.140 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 103 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2017 | 39 | 0.140 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 20 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 452 | 0.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 657 | 0.140 |
Why?
|
| Attitude | 1 | 2017 | 96 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2017 | 115 | 0.140 |
Why?
|
| Prosthesis Design | 1 | 2017 | 209 | 0.140 |
Why?
|
| Device Removal | 1 | 2017 | 64 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 441 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 146 | 0.130 |
Why?
|
| Influenza, Human | 1 | 2019 | 191 | 0.130 |
Why?
|
| Lyme Disease | 1 | 2017 | 104 | 0.130 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 113 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 1 | 2017 | 92 | 0.130 |
Why?
|
| Equipment Design | 1 | 2017 | 329 | 0.130 |
Why?
|
| Lower Extremity | 1 | 2017 | 152 | 0.120 |
Why?
|
| Patient Selection | 1 | 2017 | 464 | 0.120 |
Why?
|
| Length of Stay | 3 | 2023 | 775 | 0.120 |
Why?
|
| Curriculum | 1 | 2018 | 558 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 730 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 2059 | 0.100 |
Why?
|
| Valsartan | 2 | 2021 | 12 | 0.090 |
Why?
|
| Aminobutyrates | 2 | 2021 | 10 | 0.090 |
Why?
|
| Trastuzumab | 2 | 2021 | 11 | 0.090 |
Why?
|
| Tetrazoles | 2 | 2021 | 21 | 0.090 |
Why?
|
| Biphenyl Compounds | 2 | 2021 | 31 | 0.090 |
Why?
|
| Drug Combinations | 2 | 2021 | 146 | 0.090 |
Why?
|
| Troponin T | 2 | 2022 | 23 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2021 | 64 | 0.090 |
Why?
|
| Inpatients | 2 | 2023 | 291 | 0.080 |
Why?
|
| Hospitals | 2 | 2022 | 375 | 0.080 |
Why?
|
| Algorithms | 2 | 2024 | 976 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2022 | 841 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1051 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2024 | 3065 | 0.060 |
Why?
|
| Dyslipidemias | 1 | 2025 | 33 | 0.060 |
Why?
|
| Canagliflozin | 1 | 2024 | 5 | 0.060 |
Why?
|
| Pericarditis | 1 | 2024 | 8 | 0.060 |
Why?
|
| Glucosides | 1 | 2024 | 13 | 0.060 |
Why?
|
| Natural Language Processing | 1 | 2024 | 47 | 0.060 |
Why?
|
| Child | 2 | 2024 | 4173 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2024 | 77 | 0.050 |
Why?
|
| Benzhydryl Compounds | 1 | 2024 | 48 | 0.050 |
Why?
|
| Cause of Death | 1 | 2024 | 210 | 0.050 |
Why?
|
| Environmental Pollution | 1 | 2023 | 12 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 130 | 0.050 |
Why?
|
| Prealbumin | 1 | 2023 | 19 | 0.050 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2023 | 12 | 0.050 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2023 | 13 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2023 | 40 | 0.050 |
Why?
|
| Mortality | 1 | 2024 | 155 | 0.050 |
Why?
|
| Mitral Valve | 1 | 2023 | 105 | 0.050 |
Why?
|
| Aortic Valve | 1 | 2024 | 173 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2024 | 260 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 122 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2024 | 335 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2023 | 197 | 0.050 |
Why?
|
| Coronary Artery Bypass | 1 | 2023 | 274 | 0.050 |
Why?
|
| Electric Countershock | 1 | 2022 | 99 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 145 | 0.050 |
Why?
|
| Arterial Pressure | 1 | 2021 | 22 | 0.050 |
Why?
|
| Endocardium | 1 | 2021 | 12 | 0.050 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2021 | 17 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2024 | 342 | 0.050 |
Why?
|
| Troponin I | 1 | 2021 | 34 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 52 | 0.040 |
Why?
|
| Niacinamide | 1 | 2020 | 32 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2023 | 311 | 0.040 |
Why?
|
| Proteasome Inhibitors | 1 | 2020 | 30 | 0.040 |
Why?
|
| Phenotype | 1 | 2024 | 1136 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 142 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 51 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 313 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 62 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 155 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2021 | 162 | 0.040 |
Why?
|
| Gadolinium | 1 | 2020 | 103 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 171 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2020 | 189 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2020 | 107 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 292 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2023 | 420 | 0.040 |
Why?
|
| Survivorship | 1 | 2018 | 12 | 0.040 |
Why?
|
| Heart-Assist Devices | 1 | 2021 | 129 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 365 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 806 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 129 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 2018 | 32 | 0.040 |
Why?
|
| Program Development | 1 | 2019 | 203 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2023 | 2372 | 0.040 |
Why?
|
| Defibrillators, Implantable | 1 | 2021 | 257 | 0.040 |
Why?
|
| Contrast Media | 1 | 2020 | 408 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 983 | 0.040 |
Why?
|
| Exercise Test | 1 | 2018 | 242 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 398 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 1782 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2019 | 470 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2017 | 92 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2018 | 179 | 0.030 |
Why?
|
| Vaccination | 1 | 2019 | 333 | 0.030 |
Why?
|
| Melanoma | 1 | 2020 | 329 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1305 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2337 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 582 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 1525 | 0.020 |
Why?
|